Saroglitazar Magnesium

Saroglitazar magnesium is a dual agonist of PPARalpha and PPARgamma (EC50s = 0.65 and 3,000 pM, respectively, in a transactivation assay in HepG2 cells). It decreases serum triglyceride, free fatty acid, and glucose levels in a db/db mouse model of diabetes when administered at doses ranging from 0.01 to 3 mg/kg per day for 12 days. It increases insulin sensitivity in an oral glucose challenge when administered at a dose of 1 mg/kg in db/db mice, as well as decreases LDL levels in hApoB100/hCETP mice and in hamsters fed a high-fat high-cholesterol diet. Saroglitazar magnesium (10 µM) reverses palmitic acid-induced decreases in the expression of mRNA encoding superoxide dismutase 1 (SOD1), SOD2, glutathione peroxidase (GPX), and catalase and increases in the expression of mRNA encoding TNF-alpha, IL-1beta, and IL-6 in HepG2 cells. It decreases hepatic inflammation and steatosis in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient high-fat diet when administered at a dose of 3 mg/kg and inhibits hepatic fibrosis in a mouse model of fibrosis induced by carbon tetrachloride.Formal Name: (T-4)-bis[(alphaS)-alpha-(ethoxy-kappaO)-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoato-kappaO]-magnesium. CAS Number: 1639792-20-3. Molecular Formula: C50H56MgN2O8S2. Formula Weight: 901.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Sparingly soluble: 1-10 mg/ml. SMILES: CC1=CC=C(C2=CC=C(SC)C=C2)N1CCOC(C=C3)=CC=C3CC4[O]([Mg+2]([O-]C4=O)([O-]C5=O)[O](C5CC6=CC=C(OCCN7C(C8=CC=C(SC)C=C8)=CC=C7C)C=C6)CC)CC. InChi Code: InChI=1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20,/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28),/q,,+2/p-2. InChi Key: UJYFZCVPOSZDMK-UHFFFAOYSA-L.